GENEDIT
GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxy™ platform solves current delivery challenges by systematically screening its nanoparticle library and providing safer and efficient delivery to target tissues. The company's tool makes therapeutic gene editing possible and is easier to use, faster and more accurate than previous gene-editing techniques and thus has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases.
GENEDIT
Industry:
Biotechnology Genetics Pharmaceutical Therapeutics
Founded:
2016-04-04
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.genedit.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
43.73 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arvinas
Arvinas focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, and autoimmune.
Denali Therapeutics
Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
Menten AI
Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
Porton Advanced Solutions
Porton Advanced Solutions provide end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Advisors List
Current Employees Featured
Founder
Investors List
Qiming Venture Partners
Qiming Venture Partners investment in Angel Round - GenEdit
Korea Investment Partners
Korea Investment Partners investment in Series A - GenEdit
KTB Network
KTB Network investment in Series A - GenEdit
IMM Investment
IMM Investment investment in Series A - GenEdit
Company K Partners
Company K Partners investment in Series A - GenEdit
Time Folio Asset Management
Time Folio Asset Management investment in Series A - GenEdit
Bow Capital
Bow Capital investment in Series A - GenEdit
Dayli Partners
Dayli Partners investment in Series A - GenEdit
Sequoia Capital
Sequoia Capital investment in Series A - GenEdit
SK Holdings
SK Holdings investment in Series A - GenEdit
Official Site Inspections
http://www.genedit.com Semrush global rank: 7.8 M Semrush visits lastest month: 437
Unable to get host informations!!!
